News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Enabling Capabilities of Inovio Biomedical Corporation’s Electroporation Delivery Technology with SIV DNA Vaccine Confirmed in Collaborative Study With National Cancer Institute
September 3, 2009
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Twitter
LinkedIn
Facebook
Email
Print
Preclinical
MORE ON THIS TOPIC
Cancer
Merck’s billion-dollar Kelun bet pays off as TROP2 improves survival in endometrial cancer
May 19, 2026
·
2 min read
·
Tristan Manalac
Drug Development
Is Revolution ‘the next oncology titan’? Truist analysts make the case
May 18, 2026
·
3 min read
·
Heather McKenzie
Deals
Regeneron, Parabilis set out to create new drug class in deal worth up to $2.3B
May 18, 2026
·
2 min read
·
Gabrielle Masson
Cancer
Regeneron misses again as melanoma combo bows to Merck’s Keytruda in Phase 3
May 18, 2026
·
2 min read
·
Tristan Manalac
